Abbott: Arthritis trials

The registry lists 39 Arthritis studies with Abbott as lead sponsor. 0 are open to participants now and 20 have results posted.

Phase 2 3Phase 3 21Phase 4 5No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid ArthritisCompletedNCT01231321Phase 3Results posted
• Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical CareCompletedNCT01163916Results posted
• Time to DMARD (Disease-Modifying Anti-Rheumatic Drug) Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in TurkeyCompletedNCT01144598Results posted
• Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic DrugsCompletedNCT01083693Results posted
• Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical UseTerminatedNCT01083160Results posted
• Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid ArthritisCompletedNCT01078571Results posted
• Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA)CompletedNCT01078116Results posted
• Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid ArthritisCompletedNCT01076959Results posted
• A Study of Adalimumab in Japanese Subjects With Rheumatoid ArthritisCompletedNCT00870467Phase 3Results posted
• Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With HumiraTerminatedNCT00761514Phase 4Results posted
• Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid ArthritisCompletedNCT00690573Phase 3Results posted
• Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week DosingCompletedNCT00647270Phase 3Results posted
• Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid ArthritisCompletedNCT00603993Phase 3Results posted
• Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With MethotrexateCompletedNCT00538902Phase 2/3Results posted
• Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid ArthritisCompletedNCT00420927Phase 4Results posted
• Adalimumab in Adult Japanese Subjects With Rheumatoid ArthritisCompletedNCT00235872Phase 3Results posted
• Post-marketing Observational Study in Subjects With Rheumatoid ArthritisCompletedNCT00234884Results posted
• Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.CompletedNCT00195702Phase 3Results posted
• Long Term Open Label Continuation StudyCompletedNCT00195650Phase 3Results posted
• Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)CompletedNCT00048542Phase 3Results posted
• Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical RoutineWithdrawnNCT01078610
• Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody AdalimumabApproved for marketingNCT00650390
• Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid ArthritisApproved for marketingNCT00650026
• Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid ArthritisCompletedNCT00649922Phase 4
• Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid ArthritisApproved for marketingNCT00649545
• Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With MethotrexateCompletedNCT00647920Phase 3
• A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid ArthritisCompletedNCT00647491Phase 2/3
• Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic ArthritisCompletedNCT00646386Phase 2
• Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug TherapyCompletedNCT00646178Phase 3
• A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid ArthritisCompletedNCT00448383Phase 3
• A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)CompletedNCT00427362Phase 3
• Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With MethotrexateCompletedNCT00235859Phase 3
• Quality of Life Study With Adalimumab in Rheumatoid ArthritisCompletedNCT00234936Phase 3
• Efficacy of HUMIRA in Subjects With Active Rheumatoid ArthritisCompletedNCT00234897Phase 4
• Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid ArthritisCompletedNCT00234845Phase 3
• A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid ArthritisCompletedNCT00233571Phase 3
• Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid ArthritisTerminatedNCT00233558Phase 4
• Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic ArthritisCompletedNCT00195689Phase 3
• Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid ArthritisCompletedNCT00049751Phase 3